(Q36654338)

15 August 2017

1 reference

title

Prevention of breast cancer: current state of the science and future opportunities (English)

1 reference

15 August 2017

Ivan P Uray

1

1 reference

15 August 2017

Powel H Brown

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

1583-1600

1 reference

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Understanding breast cancer risk -- where do we stand in 2005?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Lifetime recreational exercise activity and breast cancer risk among black women and white women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Cardiovascular effects of raloxifene: the arterial and venous systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The effect of estrogens and antiestrogens in a rat model for hot flush.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Clinical use of aromatase inhibitors in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Endocrine therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Aromatase inhibitors as adjuvant therapies in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The role of aromasin in the hormonal therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

LHRH agonists and the prevention of breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Retinoid X receptors: X-ploring their (patho)physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Nuclear receptor that identifies a novel retinoic acid response pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

9-cis retinoic acid is a high affinity ligand for the retinoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Chemoprevention of breast cancer with fenretinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Sulindac for polyposis of the colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Prospective study of regular aspirin use and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Nonsteroidal antiinflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

COX-2 inhibitors for the prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Failing survival advantage in crucial trial, future of Iressa is in jeopardy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

A review of erlotinib and its clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Aromatase and COX-2 expression in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

Prevention strategies with aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.12.1583

10.1517/13543784.15.12.1583

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference